Drug Discovery Services: How to Choose the Right CRO
A practical guide to defining scope, comparing CRO capabilities, protecting decision rights, and testing a partner before committing a program.
Drug discovery services can supply a single assay, a specialist discipline, or an integrated path from target work through candidate selection. The right choice depends less on the length of a provider’s capability list than on whether its scientists, data standards, governance, and handoffs fit the next decision your program must make.
Start with a decision-ready work package: define the biological question, the evidence required, acceptance criteria, ownership of methods and data, and what happens when results challenge the original hypothesis. Then compare providers against that scope.
What drug discovery services include
In the FDA’s high-level pathway, discovery and development begin in the laboratory, while preclinical research uses laboratory and animal testing to answer basic safety questions.1 In practice, outsourced discovery work may cover target identification and validation, assay development, hit finding, medicinal and computational chemistry, structural biology, DMPK, in vitro and in vivo pharmacology, formulation, and early safety work. The exact boundary varies by provider and contract.
That variation is why buyers should purchase an answer to a defined scientific question, not an undifferentiated menu of techniques. For example, an assay-development package should state the intended biological relevance, controls, performance measures, raw-data format, and transfer expectations. The NCATS Assay Guidance Manual program emphasizes robust assay development, reproducibility, and attention to artifacts and interferences in early drug discovery.2
Beyond contracted laboratory work, teams may use the Patsnap Eureka Life Sciences workspace to evaluate targets, mechanisms, and translational risk before deciding what merits lab work.3 This is an adjacent intelligence workflow, not a CRO, wet-lab service, or substitute for experimental validation.
“Drug discovery” is not the same as clinical development or commercial manufacturing. If a proposal extends into IND-enabling work, CMC, regulatory support, or clinical operations, define those deliverables and quality systems separately.
Choose the service model before the provider
Standalone or fee-for-service work
A fixed or modular package works best when the question, methods, deliverables, and acceptance criteria are stable. Typical examples include protein production, a screening campaign, compound synthesis, a panel of ADME assays, or a defined in vivo study. The main benefit is scope clarity. The main risk is that every change in scientific direction may require a new quotation or amendment.
FTE or dedicated-team support
A full-time-equivalent model provides capacity around an evolving program rather than a single fixed output. It can suit iterative medicinal chemistry and design–make–test–analyze cycles, where priorities change as data arrive. Buyers should still define governance: who sets priorities, how effort is reported, which expertise is included, and when underused capacity can be reallocated.
Integrated discovery
An integrated program combines disciplines under a coordinated scientific and project-management structure. It can reduce handoff burden, but integration should be demonstrated rather than assumed. Ask how biology, chemistry, DMPK, pharmacology, formulation, and data systems exchange results; who owns the compound strategy; and how independent challenge is built into stage-gate decisions.
How to evaluate drug discovery services
1. Match the provider to the next decision
Write down the next irreversible or expensive decision: validate a target, select a hit series, nominate a lead, enter in vivo efficacy work, or prepare a candidate package. Then work backward to the minimum evidence needed. A provider with a narrower but well-aligned capability may be more useful than a broad provider whose workflow does not produce the evidence your governance body expects.
2. Test scientific depth and assay quality
Ask the proposed scientific lead to critique the work package before pricing it. Strong questions cover biological relevance, reference compounds, counter-screens, orthogonal confirmation, reproducibility, assay transfer, known interference modes, and how unexpected results will be investigated. Request example data structures and reports with confidential information removed.
3. Inspect data, informatics, and traceability
Specify what you will receive: raw instrument files, processed data, analysis scripts or settings, plate maps, sample lineage, compound identifiers, protocols, deviations, and final reports. Confirm how data corrections are documented and how your team can retrieve a complete record after the engagement ends.
4. Protect IP and decision rights
Contracts should distinguish your background IP, provider background IP, project-generated inventions, data ownership, method improvements, publication rights, subcontractor obligations, and the process for invention disclosure. Before externalizing sensitive chemistry or biology, involve qualified counsel. As a separate IP workflow, Patsnap Eureka IP Search supports novelty and freedom-to-operate searches with source-linked evidence for review; it does not replace contract drafting, ownership analysis, or legal advice.8
5. Examine handoffs and continuity
Map every transfer point: compounds, cell lines, methods, data, models, and scientific rationale. Ask who approves a handoff, what acceptance test applies, and how failures are resolved. If the provider uses affiliates or subcontractors, identify them in advance and apply the same confidentiality, quality, and data-return requirements.
Illustrative drug discovery services providers to research
The following examples are non-exhaustive and are not a ranking. They illustrate different combinations of integrated and specialist capabilities. Verify current scope, site, modality experience, capacity, and contractual terms directly with each provider.
Charles River Laboratories
Charles River’s hit-to-lead offering combines design and synthesis with biological evaluation and may include early ADME assessment, CADD, chemical synthesis, and target-engagement biomarker assays. The company states that this work is available through stand-alone, fee-for-service, and integrated models.4
Review the official hit-to-lead service page →Evotec
Evotec lists target identification and validation, hit identification, structural biology, molecular design and medicinal chemistry, in vitro biology, in vivo pharmacology, safety assessment, early formulation, and ADME/PK within its discovery toolbox.5
Review the official drug discovery services page →Sygnature Discovery
Sygnature describes integrated programs from target identification through candidate work, alongside standalone disciplines that include CADD, protein and structural biology, bioscience, chemistry, DMPK, in vivo pharmacology, and formulation.6
Review the official integrated discovery page →Domainex
Domainex describes screening cascades that can combine primary potency, selectivity, in vitro ADME/PK, cellular, and phenotypic assays across hit identification, hit-to-lead, and lead optimization, with medicinal, computational, and analytical chemistry support.7
Review the official screening services page →Run a pilot before scaling the relationship
A pilot should test the operating relationship as well as the science. Choose a bounded work package that exercises the interfaces most likely to matter later: scientific challenge, data transfer, project communication, and decision-making under uncertainty. Avoid a showcase task that cannot reveal how the team handles ambiguity or negative data.
A practical pilot checklist
- Named scientific lead and escalation path
- Written hypothesis and decision criteria
- Controls, replicates, counter-screens, and deviations
- Raw-data and metadata delivery format
- Weekly decision log and action owners
- Change-control and budget approval process
- IP, confidentiality, and subcontractor terms
- Method and material transfer plan
- Closeout package and archive access
- Pre-agreed stop, repeat, and expand rules
Scale the engagement only when the pilot shows that the provider can produce interpretable evidence, surface uncertainty early, and return a complete record—not merely when the headline result is positive.
Frequently asked questions
What is included in drug discovery services?
What is the difference between a CRO and a drug discovery platform?
Should a biotech use one integrated CRO or several specialists?
How should drug discovery services be priced?
Who should review a CRO agreement?
Sources and verification
- The Drug Development Process, U.S. Food and Drug Administration.
- Assay Guidance Manual Program, National Center for Advancing Translational Sciences.
- Patsnap Eureka: AI Agents for IP, R&D, Life Sciences & Materials, Patsnap.
- Hit-to-Lead in Drug Discovery, Charles River Laboratories.
- Drug Discovery Services, Evotec.
- Integrated Drug Discovery, Sygnature Discovery.
- Fragment and Compound Screening, Domainex.
- AI Patent Search, FTO & Design Clearance, Patsnap Eureka.
Sources were checked on July 28, 2026. Provider descriptions reflect current public pages and do not constitute independent testing, a ranking, or confirmation of availability at a specific site. This article is general information, not scientific, regulatory, procurement, or legal advice.
Evaluate the evidence before it reaches the lab
Explore Patsnap Eureka’s Life Sciences workspace for target, mechanism, and translational-risk research. It complements—rather than replaces—experimental drug discovery services.
Explore Eureka Life Sciences →
